Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland.
University of Turku, Turku, Finland.
J Perinat Med. 2020 Dec 21;49(4):431-438. doi: 10.1515/jpm-2020-0379. Print 2021 May 26.
Gestational IDA has been linked to adverse maternal and neonatal outcomes, but the impact of iron supplementation on outcome measures remains unclear. Our objective was to assess the effects of gestational IDA on pregnancy outcomes and compare outcomes in pregnancies treated with either oral or intravenous iron supplementation.
We evaluated maternal and neonatal outcomes in 215 pregnancies complicated with gestational IDA (Hb<100 g/L) and delivered in our tertiary unit between January 2016 and October 2018. All pregnancies from the same period served as a reference group (n=11,545). 163 anemic mothers received oral iron supplementation, and 52 mothers received intravenous iron supplementation.
Gestational IDA was associated with an increased risk of preterm birth (10.2% vs. 6.1%, p=0.009) and fetal growth restriction (FGR) (1.9% vs. 0.3%, p=0.006). The gestational IDA group that received intravenous iron supplementation had a greater increase in Hb levels compared to those who received oral medication (18.0 g/L vs. 10.0 g/L, p<0.001), but no statistically significant differences in maternal and neonatal outcomes were detected.
Compared to the reference group, prematurity, FGR, postpartum infections, and extended hospital stays were more common among mothers with gestational IDA, causing an additional burden on the families and the healthcare system.
妊娠期缺铁性贫血与不良母婴结局相关，但铁补充对结局指标的影响仍不清楚。我们的目的是评估妊娠期缺铁性贫血对妊娠结局的影响，并比较口服和静脉铁补充治疗的结局。
我们评估了 2016 年 1 月至 2018 年 10 月期间在我们的三级单位分娩的 215 例妊娠期缺铁性贫血（Hb<100 g/L）孕妇及其新生儿的结局。同期所有妊娠作为对照组（n=11545）。163 例贫血孕妇接受口服铁补充治疗，52 例孕妇接受静脉铁补充治疗。
妊娠期缺铁性贫血与早产风险增加相关（10.2%比 6.1%，p=0.009）和胎儿生长受限（FGR）（1.9%比 0.3%，p=0.006）。接受静脉铁补充的妊娠期缺铁性贫血组 Hb 水平升高幅度大于口服药物组（18.0 g/L 比 10.0 g/L，p<0.001），但母婴结局无统计学差异。
与对照组相比，妊娠期缺铁性贫血孕妇更常发生早产、FGR、产后感染和延长住院时间，给家庭和医疗保健系统带来额外负担。
